Self Study Module 2 - Considering BCMA Therapies in Clinical Trial for Relapsed/Refractory Multiple Myeloma
October 01, 2021
The accreditation for this activity has expired.
Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California
Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma. She treats patients at the Hematology and Blood Marrow and Transplant Clinic at the University of California, San Francisco, where she is a Professor of Clinical Medicine, Division of Hematology-Oncology, Department of Medicine. Dr Shah received her bachelor’s degree at Harvard University in cognitive neuroscience, followed by a medical degree from New York University School of Medicine. She then completed a residency in internal medicine at Columbia University, followed by a fellowship in hematology/oncology at University of Texas MD Anderson Cancer Center.
Dr. Shah’s areas of professional interest include the interactions between oncology and immunology, as well as helping her patients to fight multiple myeloma by boosting their immune systems. Dr. Shah belongs to the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation.
Peter Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina
Dr. Peter Voorhees is a hematologist/oncologist and the director of Medical Operations and Outreach Services in the Department of Hematology/Oncology at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees received his medical degree at the University of Michigan Medical School, and completed his residency at the University of Wisconsin School of Medicine and Public Health and a fellowship at the University of North Carolina School of Medicine.Dr. Voorhees’ clinical interest is in hematologic malignancies with a focus on plasma cell dyscrasias. His research focuses on the basis of chemotherapy resistance in multiple myeloma and the development of therapeutic strategies that overcome that resistance. He is also interested in the basis of chemotherapy-related toxicity and the development of tools that predict for treatment-related adverse events. Dr. Voorhees is board certified in hematology with the American Board of Internal Medicine.
